Hydroxychloroquine Not Recommended for COVID-19 by NIH |
This week the National Institutes of Health issued treatment guidelines for the management of COVID-19. It does not include the use of pharmaceutical agents for pre or post-exposure prophylaxis, including hydroxychloroquine, except within the confines of a clinical trial. This comes as good news to the rheumatology community. More in this article.
|
|
Early Data is in for the COVID-19 Rheumatology Registry |
The international registry that was created in March to track rheumatology patients who have contracted COVID-19, has released data from the first 110 cases from six continents.
|
|
Osteoporosis Treatments Feared and Underused |
Despite an apparent and increasing need for osteoporosis treatments, fewer people today are taking the medications both here in the United States and abroad.
|
|
|
|
Visit Rheumatology Network for easy access to new job opportunities in rheumatology. As a service to our readers, we've posted a national "Job Board" in the upper right-hand corner of the site. Suggestions for other content sections? Email the editor at areyes@mmhgroup.com.
|
|
|
|
| |